Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetLaurent Peyrin‐Biroulet, Sarah O’Donnell, Benjamin Pariente et al.|The American Journal of Gastroenterology|2015Cited by 1.8k
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, Remo Panaccione et al.|The Lancet|2022Cited by 383
Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensusArnaud Bourreille, A. Van Gossum, Aleksandra Ignjatović et al.|Endoscopy|2009Cited by 332
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Geert D’Haens, Remo Panaccione et al.|The Lancet|2022Cited by 312
Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel diseaseAlba Garrido-Trigo, Azucena Salas, A M Corraliza et al.|Nature Communications|2023Cited by 280